

Opadry[®] Enteric Product Information

Opadry Enteric is a family of fully formulated, delayed release coating systems for solid oral dosage forms, which are applied by organic or hydro-alcoholic processing techniques.

Specific Opadry Enteric coating formulations have been developed from a choice of enteric polymers, with solubility as a function of the environmental pH in the gastro-intestinal tract. The various Opadry Enteric products available from Colorcon are listed below along with the constituent enteric polymer and pH at which the system starts to dissolve.

Opadry Enteric	Polymer	Polymer Dissolution pH
91 series	Polyvinyl Acetate Phthalate (PVAP)	pH 5.0
94 series	Methacrylic Acid Copolymer (Methacrylic acid-methyl methacrylate 1:1 copolymer)	pH 6.0
95 series	Methacrylic Acid Copolymer (Methacrylic acid-methyl methacrylate 1:2 copolymer)	pH 7.0

OPADRY ENTERIC - 91 SERIES

Opadry Enteric- 91series is formulated using the delayed-release polymer Polyvinyl Acetate Phthalate NF (PVAP, Phthalavin).

Features	Benefits
<ul style="list-style-type: none">Fully formulated systemLess susceptible to hydrolysisHigh coating solids concentration (15% coating solids using a hydro-alcoholic solvent system; 5-8% coating solids for an organic solvent system)Pigmented or clear systems are availableSimple to dispense and dispense in solvent systems (45 minutes at low shear)Enteric protection is achieved with 6-8% coating weight gain on tablets**Polymer start to dissolve at pH 5.0 above	<ul style="list-style-type: none">Time and cost savingsStable produce (12 months re-evaluation period**)Produces elegant glossy coatings while exhibiting excellent enteric protectionAllows rapid coating applicationProvides rapid, reproducible drug release in alkaline dissolution media

Regulatory

- Acceptable for use in pharmaceutical enteric coatings in the U.S. and other countries that accept NF compliance. Not acceptable for use in dietary supplement coatings in the U.S.
- Currently no precedence of use for PVAP in Japan exists for pharmaceutical or dietary supplement coatings.

Applications

- Tablets, soft-gelatin capsules, hard-gelatin capsules and multi-particulates.

Packaging

- 25 kg carton with double polyethylene bags and desiccant between bags.

Recommended Storage Conditions

- Seal container tightly.
- Keep below 30°C / 80°F; not more than 65% relative humidity. Product packaging contains desiccant.

Re-evaluation Period (Warranty)

- 12- months from date of manufacture*

* May vary based on pigment selection.

** To be determined on a case-by-case basis.

OPADRY ENTERIC - 94 SERIES

Opadry Enteric- 94series is formulated using the delayed-release polymer

Methacrylic Acid Copolymer, Type A USP/ NF

Methacrylic Acid- Methyl Methacrylate Copolymer (1:1) Ph. Eur

Methacrylic Acid Copolymer L JPE

Features	Benefits
Fully formulated system	Time and cost savings
Non-tacky	Processing ease
Hydro-alcoholic solvents are recommended	Allows rapid coating application
Pigmented or clear systems are available	Produces elegant glossy coatings while exhibiting excellent enteric protection
Simple to dispense and disperse in solvent systems (45 minutes at low shear)	Provides rapid, reproducible drug release in alkaline dissolution media.
Enteric protection is achieved with 5-6% coating weight gain on tablets**	Stable product (12 months re-evaluation period*)
Polymer start to dissolve at pH 6.0 and above	
Methacrylic acid copolymers have excellent stability against hydrolysis	

Regulatory

- Acceptable for use in pharmaceutical enteric coatings in the U.S. and other countries that accept NF compliance.
- Not acceptable for use in dietary supplement coatings in the U.S.

Applications

- Tablets, soft-gelatin capsules, hard-gelatin capsules and multi-particulates.

Packaging

- 25 kg carton with double polyethylene bags and desiccant between bags.

Recommended Storage Conditions

- Seal container tightly.
- Keep below 30°C / 86°F; not more than 65% relative humidity. Product packaging contains desiccant.

Re-evaluation Period (Warranty)

- 12- months from date of manufacture*

* May vary based on pigment selection.

** To be determined on a case-by-case basis.

REFERENCES

1. Hogan, J. E. (1995). Modified Release Coatings. In: G. Cole (Ed.) *Pharmaceutical Coating Technology* (p. 435). London: Taylor & Francis Ltd.
2. Lehmann, K. (1997). Polymethacrylate Coating Systems. In: McGinity J (Ed.) *Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms* (p.136) New York: Marcel Dekker Inc.

The information contained herein, to the best of Colorcon, Inc.'s knowledge is true and accurate. Any recommendations or suggestions of Colorcon, Inc. with regard to the products provided by Colorcon, Inc. are made without warranty, either implied or expressed, because of the variations in methods, conditions and equipment which may be used in commercially processing the products, and no such warranties are made for the suitability of the products for any applications that you may have disclosed. Colorcon, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages.

Colorcon, Inc. makes no warranty, either expressed or implied, that the use of the products provided by Colorcon, Inc., will not infringe any trademark, trade name, copyright, patent or other rights held by any third person or entity when used in the customer's application.

For more information, contact your Colorcon representative or call:

North America
+1-215-699-7733

Europe/Middle East/Africa
+44-(0)-1322-293000

Asia Pacific
+65-6438-0318

Latin America
+54-11-5556-7700

You can also visit our website at www.colorcon.com



© BPSI Holdings LLC, 2013.

The information contained in this document is proprietary to Colorcon and may not be used or disseminated inappropriately.

All trademarks, except where noted, are property of BPSI Holdings, LLC.

Pi_opadryenteric_91&94_Series_ver2_12_2013